Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Polycystic Ovary Syndrome 7Neoplasms 6Breast Neoplasms 6Vomiting 2Solid Tumors 2Skin Neoplasms 2Neoplasm Metastasis 2Melanoma 2Diabetes Mellitus 2Weight Gain 1Venous Thromboembolism 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Stem Cell Transplant Complications 1Skin Toxicity 1Renal Insufficiency 1Prostatic Neoplasms 1Primary Myelofibrosis 1Premature Birth 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-Eclampsia 1Polycythemia Vera 1Parathyroid Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Nausea 1Myeloproliferative Disorders 1Multiple Myeloma 1

Interventions

Carboplatin 41Paclitaxel 32Radiotherapy 28Cisplatin 25Bevacizumab 24Erlotinib Hydrochloride 19Pemetrexed 18Docetaxel 16Gemcitabine 15Gefitinib 8Vinorelbine 7Taxes 7Cetuximab 7ceritinib 5Surgical Procedures, Operative 5Etoposide 5Amplified Fragment Length Polymorphism Analysis 5sargramostim 3pembrolizumab 3capmatinib 3Radiotherapy, Conformal 3Radiation 3Gene Expression Profiling 3Cyclophosphamide 32-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 3trametinib 2pegfilgrastim 2osimertinib 2Topotecan 2Tirapazamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma of Lung × Tablets × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡